Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5912076 | Multiple Sclerosis and Related Disorders | 2016 | 20 Pages |
Abstract
Compared with placebo, clear reductions in ARR with disease-modifying therapies were accompanied by more uncertain changes in disability progression. The magnitude of the reduction and the uncertainty associated with treatment effects varied between DMTs. While natalizumab and alemtuzumab demonstrated consistently high ranking across outcomes, with older interferon-beta and glatiramer acetate products ranking lowest, variation in disability progression definitions lead to variation in the relative ranking of treatments. Rigorously conducted comparative studies are required to fully evaluate the comparative treatment effects of disease modifying therapies for RRMS.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Emer Fogarty, Susanne Schmitz, Niall Tubridy, Cathal Walsh, Michael Barry,